Archives
-
Mifepristone, AR Heterogeneity, and Evidence Limits
2026-10-16
The cited prostate cancer study shows that androgen receptor heterogeneity is associated with distinct castration and enzalutamide responses, but it does not establish efficacy for Mifepristone (RU486), which acts primarily through progesterone-receptor biology. The findings are valuable for interpreting receptor-dependent cancer phenotypes, while supplier claims about other tumor and reproductive endpoints require separate, endpoint-specific evidence.
-
Omeprazole: Identity, Mechanism, and Evidence Limits
2026-10-15
The APExBIO listing identifies Omeprazole, SKU A2845, as a 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide H+,K+-ATPase inhibitor and reports assay-specific IC50 values for proton-pump inhibition and histamine-induced acid formation. Those claims establish the product’s stated research context, but the available information does not provide an identity-matched study, model details, comparators, uncertainty estimates, or independent evidence of antiulcer efficacy.
-
AZ505 and SMYD2 in Cisplatin-Associated Renal Fibrosis
2026-10-15
A literature-focused analysis of a 2023 study linking pharmacological SMYD2 inhibition with reduced cisplatin-associated kidney injury, inflammation, and fibrosis in mice and cultured tubular epithelial cells. The findings support SMYD2 as a candidate regulator in this model, but do not establish clinical efficacy, supplier-specific performance, or a fully resolved molecular mechanism.
-
What G-15 Shows About Spinal GPR30 Signaling
2026-10-14
Evidence from a 2024 eLife study supports a role for spinal GPR30 in chronic constriction injury–associated neuropathic pain in mice. The study linked GPR30 upregulation in the spinal dorsal horn to behavioral hypersensitivity, neuronal activation, AMPA-dependent excitatory transmission in CCK-positive neurons, and descending input from primary sensory cortex. Pharmacological blockade with G-15 was concordant with cell-type and circuit-level manipulations, but the findings remain model- and context-dependent. They establish mechanistic evidence for spinal GPR30 involvement rather than clinical validation of a GPR30 therapy or proof that every commercial formulation of G-15 has identical properties.
-
Omeprazole: Identity and Evidence Boundaries
2026-10-14
APExBIO lists Omeprazole (SKU A2845) as an H+,K+-ATPase inhibitor for conceptual work on gastric acid secretion and related antiulcer research. No matched paper or independent study record was provided, so the available evidence supports catalog-level identity and intended research scope—not validated efficacy, mechanism, or practical recommendations.
-
E. histolytica Prx and Macrophage Autophagy
2026-10-13
Li and colleagues investigated whether peroxiredoxin from Entamoeba histolytica can alter autophagy in host macrophages. Their findings associate recombinant parasite Prx with autophagosome formation, cytotoxicity, and activation of a TLR4–TRIF-associated pathway in cultured macrophages and mice. The evidence supports a possible host-cell mechanism contributing to parasite pathogenesis, but does not establish that Prx alone reproduces infection biology or that the mechanism is independent of other cellular stress responses. Wortmannin and related PI3K inhibitor claims are contextual here: the cited study does not demonstrate a PI3K/Akt/mTOR mechanism.
-
α-KGA, PDHA1 Succinylation in Cholangiocarcinoma
2026-10-13
A source-grounded overview of a 2025 Nature Communications study linking PDHA1 succinylation, alpha-ketoglutarate accumulation, macrophage antigen presentation and chemotherapy response in preclinical cholangiocarcinoma models.
-
Thermal Shift Assays for Bacterial Sensor Ligands
2026-10-12
A source-grounded overview of a 2025 review on thermal shift assays for identifying ligands of bacterial sensor proteins, emphasizing its conceptual framework, evidentiary limits, and distinction from broad commercial compound-library claims.
-
Omeprazole: Identity and Evidence Scope
2026-10-12
A source-limited overview of the catalogued identity, conceptual research scope, reported supplier claims, and evidence limitations for Omeprazole SKU A2845.
-
SGI-1027 and Everolimus in Renal Cancer
2026-10-10
A 2024 Advanced Science study reports that the DNMT1 inhibitor SGI-1027 induces methuosis-like vacuolation and cooperates with everolimus to promote lysosome-associated apoptosis and GSDME-dependent pyroptosis in renal cancer models. The work provides a preclinical rationale for targeting lysosomal membrane permeability as a route to address limitations of mTOR-directed therapy, while its clinical relevance remains to be established.
-
FLASH-RT and EGCG Nanoparticles: Study Findings
2026-10-09
A 2026 International Journal of Nanomedicine study reports that functionalized, self-assembled EGCG nanoparticles, termed BENPs, increased tumor-cell damage and immune activation when combined with FLASH-RT in breast cancer models. The findings support EGCG-based radiosensitization as a research strategy, while remaining preclinical and dependent on validation across radiation systems, tumor models, and immune contexts.
-
Machine-Learning Discovery of Senolytics
2026-10-09
The Nature Communications study by Smer-Barreto and colleagues shows how machine-learning models trained only on published data can prioritize senolytic candidates from chemical libraries. The authors validated ginkgetin, periplocin, and oleandrin in human cell systems, while also demonstrating both the promise and the limitations of data-driven early drug discovery.
-
Tandem ssDNA, Thrombin, and Immunothrombosis
2026-10-08
A 2025 PNAS study identifies tandem single-stranded ATTCC repeats in neutrophil extracellular traps as selective thrombin-binding elements. The findings expand the mechanistic view of NET-driven coagulation and support sequence-directed disruption of NET–thrombin interactions, while remaining preliminary for therapeutic translation.
-
mTORC1–IRE1α Signaling in Palmitate Lipotoxicity
2026-10-08
Wang and colleagues identify mTORC1–IRE1α signaling as a mechanistic contributor to palmitate-induced triglyceride overproduction and cell death in AML12 hepatocytes. The findings connect fatty-acid metabolism, mTORC1 activation, and endoplasmic-reticulum stress, while remaining limited to a cell-based model rather than demonstrating a clinical or in vivo treatment effect.
-
Omeprazole A2845: Product Overview
2026-10-07
Omeprazole (SKU A2845) is presented by APExBIO as a research-use H+,K+-ATPase inhibitor for conceptual studies of gastric acid secretion and antiulcer mechanisms. No matched paper evidence was supplied, so vendor-reported activity and applicability remain unverified here.